Fenebrutinib and BTK inhibition: Unveiling a new target for the treatment of chronic spontaneous urticaria. Carvallo A, Sanchez-Fernandez S, Morales-Palacios MP. Allergy 2023;78:603-605.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Carvallo A, Sanchez-Fernandez S, Morales-Palacios MP. Fenebrutinib and BTK inhibition: Unveiling a new target for the treatment of chronic spontaneous urticaria. Allergy 2023;78:603-605.
PMID: 36420759